Phase 4 N=10 Minocycline Augmentation to Clozapine
Schizophrenia · Schizoaffective Disorder
Primary: Positive Subscale Score of the Positive and Negative Syndrome Scale (PANSS) — 22; 22.33; 16; 20.33 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=18 Effect of DPP4 Inhibition on Vasoconstriction
Type 2 Diabetes Mellitus
Primary: Forearm Blood Flow — 1.72; 2.29; 1.17; 1.63 mL/min/100 mL
Phase 4 N=80 Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast
Plaque Psoriasis
Primary: Percentage of Participants With a PASI 75 Response at Week 12 — 41.6 percentage of participants
Phase 4 N=54 Reversing Corticosteroid Induced Memory Impairment
Memory Impairment
Primary: The Rey Auditory Verbal Learning Test (RAVLT) — 45.741; 43.286 T Score
Phase 4 N=43 Evaluation of Electronic LogMar Visual Acuity and Contrast Sensitivity in a Population of Contact Lens Wearers
Visual Acuity
Primary: Visual Acuity (logMAR) — 0.15; 0.21; 0.02; 0.05 logMAR
Phase 4 N=140 ADA Linagliptin in Long Term Care
Diabetes
Primary: Mean Fasting Blood Glucose Level — 136.4; 131.2 mg/dl
Phase 4 N=93 Parasternal Nerve Block Using Bupivacaine for Postoperative Analgesia in Children Undergoing Cardiac Surgery
Pain
Primary: Total Fentanyl/Equivalent Day 0-1 — 23.6; 22.4 mcg/kg/day
Phase 4 N=173 Neurocognitive and Metabolic Effects of Mild Hypothyroidism
Hypothyroidism
Primary: Executive Function — 7.9; 7.5; 8.8 units on a scale
Phase 4 N=15 Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide
Breast Cancer · Obesity
Primary: Clearance (Cl) for Doxorubicin and Cyclophosphamide — 1.85 L/hr
Phase 4 N=20 Reducing Suicidal Ideation Through Treatment of Nightmares-Post Traumatic Stress Disorder (PTSD)
Post Traumatic Stress Disorder · Suicidal Ideation · Nightmares
Primary: Change Score for Scale for Suicide Ideation — 7.6; 8.2 units on a scale
Phase 4 N=20 Understanding Experimentally Induced Hot Flushes
Hot Flashes
Primary: Percent Change in Objective Sleep Efficiency — -2.6; 4.2 percent change
Phase 4 N=38 Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).
Colitis, Ulcerative
Primary: Serum ST2 Level at Week 6 — 21.8 ng/mL
Phase 4 N=638 A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus
Type 1 Diabetes Mellitus
Primary: Percentage of Time of Mean Glucose Concentration Within the Target Range of 70-180 mg/dL as Obtained From CGM — 55.40; 55.18 percentage of time — p=0.8494
Phase 4 N=861 Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®
Multiple Sclerosis
Primary: Change From Baseline in the Medication Satisfaction Questionnaire (MSQ) to Month 6 Using a Repeated Measures ANCOVA — 5.396; 5.717 units on a scale — p=<0.001
Phase 4 N=221 Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD
Pulmonary Disease, Chronic Obstructive
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) (in Liter) After 28 Days of Treatment — 1.422; 1.399 Liter — p=<0.0001